Loading viewer...
investor_presentation
Format: PDF investor_presentation
Shield Therapeutics is a London AIM-listed pharmaceutical company focused on developing and commercializing Accrufer®/Feraccru®, a novel oral treatment for iron deficiency in adults approved in the US and EU. The company commenced US commercialization in Q3 2021 and has out-licensed ex-US rights to Norgine, ASK Pharma, and Korea Pharma for key markets including Europe, China, and South Korea.
investor_presentation
36 Pages
Wipro Limited
Tempur Sealy (TPX) October 2016 Research Analysis
investor_presentationinvestor_presentation
12 Pages
Tempur Sealy International